Skip to main content
Premium Trial:

Request an Annual Quote

Bruker, Nextval Link Technology Platforms for Drug Screening

NEW YORK (GenomeWeb News) – Bruker and Nextval are collaborating on the high-throughput screening of drugs and their metabolites using both companies' platforms, Bruker announced today.

Bruker's ultrafleXtreme MALDI-TOF/TOF mass spectrometer and Nextval's MassInsight technology will be used in the partnership.

The ultrafleXtreme "combines the acquisition speed of its 2 kHz smartbeam laser with its Perpetual Ion Source for optimum performance for low concentration high-throughput screening," Bruker said, adding that Nextval's screening technology will be integrated with Bruker's Compass software to maximize sample density and reduce sample analysis costs.

Meanwhile, Nextval's MassInsight technology, based on novel surface chemistries coupled with microarray acoustic deposition methods, addresses needs in the pharmaceutical and testing and industrial markets.

Based in San Diego, Nextval develops high-throughput, high-content, mass-based screening assays. The firm was recently was awarded a Phase II SBIR grant to further develop and commercialize the MassInsight technology for high-throughput enzyme assays.

Financial and other terms of the deal were not disclosed.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.